viernes, 10 de marzo de 2017

NCT01863550 Clinical Trial - National Cancer Institute

NCT01863550 Clinical Trial - National Cancer Institute

National Cancer Institute banner




This phase III study is for patients with newly diagnosed symptomatic multiple myeloma. It compares two combinations of drugs to see which works better as induction treatment.Then, the study’s primary goal is to study the maintenance treatment given after induction treatment.  It compares whether continuing maintenance treatment with the immunotherapy drug lenalidomide until the cancer returns is better than stopping lenalidomide maintenance treatment after 2 years. 


Bortezomib or Carfilzomib with Lenalidomide and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma

  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeTrial IDs
Phase IIIBiomarker/Laboratory analysis, Supportive care, TreatmentActive18 and overE1A11
NCI-2012-02608, ECOG-E1A11, NCT01863550

Trial Description

Summary

This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bortezomib, lenalidomide, and dexamethasone are more or less effective than carfilzomib, lenalidomide, and dexamethasone in treating patients with multiple myeloma

No hay comentarios:

Publicar un comentario en la entrada